



**The UAB Institutional Biosafety Committee Meeting Minutes  
Research Involving Recombinant and Synthetic Nucleic Acid Molecules  
November 10, 2025 12:30 pm**

<b>Members</b>	<b>Present (Y/N)</b>	<b>Vote (Y/N)</b>
1. Joel N. Glasgow, PhD, Chair [JNG]	Y	Y
2. Megan Kiedrowski, PhD, Vice-Chair [MRK]	Y	Y
3. Donna Williamson, MS, RSS [DSW]	Y	Y
4. Amanda F. Smith, BS, RSS, Voting Contact [AFS]	N	N
5. Cameron Crosby, MD, OM [JCC]	Y	Y
6. Julie Allen, DNP, OM [JSA]	Y	N
7. Lillie Flood, RN-BSN, JCDH [LF]	Y	Y
8. Qiang (John) Ding, PhD, VA [QJD]	Y	Y
9. Andrea Osborne, DVM, ARP [AJO]	N	N
10. Justin Roth, PhD, BSO-EHS [JCR]	Y	N
11. Brian Lagory, BS, BSO-EHS [BEL]	Y	Y
12. Vineel Reddy, PhD, EHS [VPR]	Y	Y
13. Julie Gray, BS, EHS [JDG]	Y	N
14. Tyler Uzzell, MA, IRB [TWU]	Y	Y
15. Amanda J. Watts, MS, IACUC [AJW]	Y	Y
16. Chad Dunaway, IACUC [CD]	N	N
17. Tyler T. Wright, PhD, Lab Rep [TTW]	Y	Y
18. Masakazu Kamata, PhD, Lab Rep [MK]	N	N
19. Kevin Harrod, PhD, Lab Rep [KH]	N	N
20. Christine M. Wright, PhD, Lab Rep [CMW]	Y	Y
21. Larisa Pereboeva, PhD, Lab Rep [LP]	Y	Y
22. Theresa Strong, PhD, Lab Rep [TVS]	Y	Y
23. Aftab Ahmad, PhD, Lab Rep [AA]	N	N
24. Adam McClintock, MBA, HSR [AM]	N	N
25. Wesley Willeford, MD, JCDH [WW]	Y	Y
26. Rebecca Johnstone, RSS, Recording Secretary [RMJ]	Y	N
<b>Total</b>	<b>19</b>	<b>15</b>

**Guests Present**

Laura Caltrider, MS, EHS [LPC]	Caitlyn Sebastian, Biomed Sciences [CS]
Earle Durboraw, MA, ARP [EBD]	Douglas Fox, PhD, SEBLAB [DMF]
Joseph Palmer, PhD, SEBLAB [JP]	Luselyz Ortiz Torres, EHS [LOT]

The November 10, 2025, Institutional Biosafety Committee (IBC) meeting for Research Involving Recombinant of Synthetic Nucleic Acid Molecules was called to order at 12:32 pm via web-based video conferencing tool by JNG. A quorum was present.

### **Welcome and Introduction of Guests**

JNG welcomed all in attendance.

### **Approval of the October 13, 2025, Minutes**

The October 13, 2025 meeting minutes were distributed in the Committee member packet via email and/or secure cloud storage prior to the meeting. A motion was made to approve the minutes. The motion was seconded. There were three abstentions. The minutes were approved.

### **Standing Reports**

- In the News/Regulatory Visits – There were no updates.
- Faculty Senate – There were no updates.
- Veterans Administration – There were no updates.
- Employee Health – There has been an increase in flu this winter, which is a normal trend.
- JCDH – There were no updates.
- IRAP and EHSA – There were no updates.
- Research Safety Updates:
  - PI Arrivals/Departures/UAB Lab Relocations – Arrivals: N/A Departures: N/A
  - Safety Visits – Top 3 Violations: Chemical inventory, peroxide formers mislabeled, and improper chemical storage


**New/Old Business** – The Viral Vectors SOP was endorsed. RSS will use building codes instead of official building names for the minutes being posted going forward starting with this meeting. Committee endorsed the Lab Audit Escalation Policy for EHS. Committee chose to tentatively move the monthly meeting to the second Tuesday of the month at 9am.

**Project Review** - The review and discussion of the following projects included: agent characteristics; types of manipulations planned; verification that the PI and laboratory staff performing the research have been appropriately trained in the safe conduct of the research; and containment control measures to be implemented (biosafety level and any special provisions). Please refer to the attached summary of the Committee review outcome for each project.

**Transgenic Projects** - No transgenic projects were discussed at this meeting.

**Adjournment** - The Chair asked if there were any further questions or comments. Being none, the meeting was adjourned at 1:38 pm. The next meeting date is December 08, 2025.

Respectfully submitted by:



Rebecca Johnstone, Recording Secretary  
Research Safety Committees

Project registration documents submitted by the PI indicate UAB Institutional Biosafety Committee (IBC) review and approval is required for the following research activities involving recombinant or synthetic nucleic acid (r/sNA) molecules and/or biohazardous agents. If the nature of the work changes or the listed conditions cannot be met, it is the PI's responsibility to consult with the IBC for additional guidance. It is the PI's responsibility to ensure all individuals listed on the project are enrolled in and compliant with the requirements of UAB Employee Health prior to and for the duration of the work:

Approve	Disapprove	Abstain or Recuse	RSC #	Evaluation
15	--	--	25-197	<p><b>Amitha Ananth: <i>An Open-label, Dose-escalation and Dose-expansion Study of the Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Females with Rett Syndrome</i></b></p> <p>Reason for IBC:</p> <ul style="list-style-type: none"> <li>Administration of rsNA Adeno-associated viral vector encoding miniMECP2 gene to one or more human subjects</li> </ul> <p>Containment:</p> <ul style="list-style-type: none"> <li>Universal precautions will be used for storage, preparation, and administration of the investigational product.</li> <li>Respiratory protection is recommended for those present in the OR suite for administration.</li> <li>Any unused IP and any potentially contaminated materials will be disposed as medical waste or per the sponsor's instructions.</li> <li>It should be clearly understood that IBC approval of the project in no way endorses or guarantees the safety of the above recombinant material for administration to humans.</li> </ul>
15	--	--	25-187	<p><b>Miranda Curtiss: <i>Chi311 In Extracellular Vesicles from Asthmatic Veterans and Relevance in Preclinical Asthma Models</i></b></p> <p>Reasons for IBC:</p> <ul style="list-style-type: none"> <li>Administration of a recombinant Risk Group 2 fungus, <i>Aspergillus fumigatus</i>, to mice</li> </ul> <p>Containment:</p> <ul style="list-style-type: none"> <li>BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with <i>Aspergillus fumigatus</i>.</li> <li>ABSL2 practices and procedures, including the use of an annually certified biosafety cabinet, shall be used for all handling or manipulations of animals administered <i>Aspergillus fumigatus</i>.</li> </ul>

				<ul style="list-style-type: none"> <li>The Animal Resources Program will be notified, via the posting of an AUSI, of <i>Aspergillus fumigatus</i> in animals.</li> <li>An agent-specific safety and data plan will be made available and reviewed by all personnel working with <i>Aspergillus fumigatus</i>.</li> </ul>
15	--	--	25-184	<p><b>Erwin Van Meir: <i>Role of BAI3 in Skin Cancers</i></b></p> <p>Reasons for IBC:</p> <ul style="list-style-type: none"> <li>Administration of rsNA modified cells to animals</li> </ul> <p>Containment:</p> <ul style="list-style-type: none"> <li>BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with human cells.</li> <li>The <a href="#">UAB Guidelines for Conducting Human Xenograft Experiments in Mice</a> or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable.</li> </ul>
15	--	--	25-190	<p><b>Eun Young Ahn: <i>Gene Therapy for ZTTK Syndrome using AAV expressing SON</i></b></p> <p>Reasons for IBC:</p> <ul style="list-style-type: none"> <li>Administration of rsNA AAV to animals.</li> </ul> <p>Containment:</p> <ul style="list-style-type: none"> <li>ABSL2 practices and procedures, including the posting of an AUSI, will be used for 14 days post-administration of AAV vectors, then ABSL1 will be used.</li> </ul>
15	--	--	25-180	<p><b>Kazumi Taguchi: <i>Elucidating a fundamental molecular mechanism of Benign Prostatic Hyperplasia</i></b></p> <p>Reasons for IBC:</p> <ul style="list-style-type: none"> <li>In vitro modification of cells using lentivirus/CRISPR Cas9</li> <li>Administration of rsNA modified cells to animals</li> </ul> <p>Containment:</p> <ul style="list-style-type: none"> <li>BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with lentivirus and human cells.</li> <li>The <a href="#">UAB Guidelines for Conducting Human Xenograft Experiments in Mice</a> or ABSL1 practices and procedures will be followed for the administration of human material to animals, as applicable.</li> <li>The UAB HIV/Lentivirus Exposure Response Plan will be made available and reviewed by all working with HIV, lentiviral vectors, or retroviral vectors.</li> </ul>
15	--	--	25-188	<p><b>Rintaro Hashizume: <i>Intranasal Delivery of Targeted Nanoliposomal Therapeutics for Pediatric Glioma</i></b></p> <p>Reasons for IBC:</p> <ul style="list-style-type: none"> <li>Administration of G027, a r/sNA oncolytic Herpes Simplex Virus-1, to animals</li> </ul>



				<p>Containment:</p> <ul style="list-style-type: none"><li>• BSL2 practices and procedures, including the use of an annually certified biosafety cabinet, will be used for all in vitro work with G027.</li><li>• ABSL2 practices and procedures, including the use of an annually certified biosafety cabinet and the posting of an AUSI, shall be used for all handling or manipulations of animals administered G027 until 14 days after the last administration.</li><li>• An agent-specific safety and data plan will be made available and reviewed by all personnel working with G027.</li></ul>
--	--	--	--	--